Adaptimmune Therapeutics PLC
NASDAQ:ADAP
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
UK |
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
281.1m USD | 11.5 | ||
US |
Abbvie Inc
NYSE:ABBV
|
284.7B USD | 35.6 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
164.1B USD | 32.7 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD | 6.3 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.6B USD | 4 | ||
AU |
CSL Ltd
ASX:CSL
|
135.3B AUD | 5.2 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
79.8B USD | 4.5 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
54.6B USD | 4.3 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 16.9 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.7B USD | 2.1 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 5 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.